Nanostics Inc.

Published purpose

Bladder cancer is the 6th most common cancer in men and the 17th most common cancer in women globally. Early diagnosis of bladder cancer is very important as it is associated with a higher survival rate, for both men and women. There is currently no clinically relevant detection test for bladder cancer. The goal of the Firm's bladder cancer project is to develop a highly accurate test that can detect clinically significant bladder cancer using machine learning and our extracellular vesicle (EV) detection platform. Similar to our successful prostate project we will first validate our selected bladder cancer biomarkers and then incorporate relevant clinical features using machine learning algorithms to create a risk score of disease.